The law is expected to start a new era for TCM. Key issues are standardization, GMP issues for manufacturing and strict legal supervision, which is expected to greatly reduce the number of TCM manufacturers and lead to larger industrial clusters with higher standards. At the research end, the combination of TCM with personalized medicine and the availability of big data is expected to lead to a more rational interpretation of phytopharmaceutical activity. Finally, TCM prescriptions will be pushed to share 30 % of all prescribed drugs in Chinese hospitals by the end of “135”.

China Bio news release, July 1, 2017